Основная статистика
| LEI | 529900ICS2ZUY1ULZR25 |
| CIK | 1351172 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Liminal Biosciences Inc
SEC Filings (Chronological Order)
На этой странице представлен полный хронологический список документов SEC, за исключением документов о собственности, которые мы предоставляем в других местах.
| October 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-39131 Liminal BioSciences Inc. (Exact name of registrant as specified in |
|
| September 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D/A (Amendment No. 4) UNDER THE SECURITIES EXCHANGE ACT OF 1934 Liminal BioSciences Inc. (Name of Issuer) Common Shares, no par value (Title of Class of Securities) 53272L202 (CUSIP Number) Eugene Siklos, President c/o Thomvest Asset Management Ltd. 65 Queen Street West, Suite 2400 Toronto, Ontario, M5H 2M8 (416) 36 |
|
| September 26, 2023 |
As filed with the Securities and Exchange Commission on September 26, 2023 As filed with the Securities and Exchange Commission on September 26, 2023 Registration No. |
|
| September 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of September 2023 Commission File Number: 001-39131 LIMINAL BIOSCIENCES INC. (Translation of registrant’s name into English) 440 Armand-Frappier Boulevard, Suite 300 Laval, Québec H7V 4B4 (Address |
|
| September 26, 2023 |
FORM 51-102F3 MATERIAL CHANGE REPORT Exhibit 99.1 FORM 51-102F3 MATERIAL CHANGE REPORT 1. Name and Address of Company Liminal BioSciences Inc. (“Liminal BioSciences” or the “Company”) 440, Armand-Frappier Blvd., Suite 300 Laval, Québec H7V 4B4 2. Date of Material Change September 26, 2023 3. News Release A news release disclosing the nature and substance of the material change was disseminated by Liminal BioSciences on September 26, |
|
| September 26, 2023 |
As filed with the Securities and Exchange Commission on September 26, 2023 As filed with the Securities and Exchange Commission on September 26, 2023 Registration No. |
|
| September 26, 2023 |
LIMINAL BIOSCIENCES ANNOUNCES COMPLETION OF THE PLAN OF ARRANGEMENT WITH STRUCTURED ALPHA LP EXHIBIT 99.1 LIMINAL BIOSCIENCES ANNOUNCES COMPLETION OF THE PLAN OF ARRANGEMENT WITH STRUCTURED ALPHA LP LAVAL, QC and CAMBRIDGE, England, Sept. 26, 2023 /CNW/ - Liminal BioSciences Inc. ("Liminal BioSciences" or the "Company") is pleased to announce that the transaction contemplated by the previously announced statutory plan of arrangement under the provisions of the Canada Business Corporations |
|
| September 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13E-3 (Amendment No. 2) RULE 13e-3 TRANSACTION STATEMENT UNDER SECTION 13(e) OF THE SECURITIES EXCHANGE ACT OF 1934 Liminal BioSciences Inc. (Name of the Issuer) Liminal BioSciences Inc. Structured Alpha LP Thomvest Asset Management Ltd. Peter J. Thomson Eugene Siklos (Name of Persons Filing Statement) Common Shares, |
|
| September 26, 2023 |
As filed with the Securities and Exchange Commission on September 26, 2023 As filed with the Securities and Exchange Commission on September 26, 2023 Registration No. |
|
| September 26, 2023 |
Exhibit 99.2 Liminal BioSciences Inc. Notice of Change in Corporate Structure pursuant to Section 4.9 of National Instrument 51-102 Continuous Disclosure Obligations Item 1 Names of the parties to the transaction Liminal BioSciences Inc. (“Liminal BioSciences”) Structured Alpha LP (the “Purchaser”). Item 2 Description of the transaction On September 26, 2023, pursuant to an arrangement agreement d |
|
| September 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of September 2023 Commission File Number: 001-39131 LIMINAL BIOSCIENCES INC. (Translation of registrant’s name into English) 440 Armand-Frappier Boulevard, Suite 300 Laval, Québec H7V 4B4 (Address |
|
| September 26, 2023 |
As filed with the Securities and Exchange Commission on September 26, 2023 As filed with the Securities and Exchange Commission on September 26, 2023 Registration No. |
|
| September 19, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of September 2023 Commission File Number: 001-39131 LIMINAL BIOSCIENCES INC. (Translation of registrant’s name into English) 440 Armand-Frappier Boulevard, Suite 300 Laval, Québec H7V 4B4 (Address |
|
| September 19, 2023 |
LIMINAL BIOSCIENCES RECEIVES FINAL COURT ORDER FOR PLAN OF ARRANGEMENT WITH STRUCTURED ALPHA LP EXHIBIT 99.1 LIMINAL BIOSCIENCES RECEIVES FINAL COURT ORDER FOR PLAN OF ARRANGEMENT WITH STRUCTURED ALPHA LP LAVAL, QC and CAMBRIDGE, England, Sept. 19, 2023 /CNW/ - Liminal BioSciences Inc. (NASDAQ: LMNL) ("Liminal BioSciences" or the "Company"), is pleased to announce that it received the final order of the Ontario Superior Court of Justice (Commercial List) approving the previously-announced pl |
|
| September 15, 2023 |
LIMINAL BIOSCIENCES SHAREHOLDERS APPROVE PLAN OF ARRANGEMENT WITH STRUCTURED ALPHA LP EXHIBIT 99.1 LIMINAL BIOSCIENCES SHAREHOLDERS APPROVE PLAN OF ARRANGEMENT WITH STRUCTURED ALPHA LP LAVAL, QC and CAMBRIDGE, England, Sept. 15, 2023 /CNW/ - Liminal BioSciences Inc. (NASDAQ: LMNL) ("Liminal BioSciences" or the "Company"), is pleased to announce that its shareholders have approved the previously-announced plan of arrangement under section 192 of the Canada Business Corporations Act |
|
| September 15, 2023 |
Exhibit 99.2 VIA SEDAR September 15, 2023 RE: Report of Voting Results pursuant to Section 11.3 of National Instrument 51-102 – Continuous Disclosure Obligations (“NI 51-102”) Following the Special Meeting of the Shareholders of Liminal BioSciences Inc. (the “Company”) held virtually on September 15, 2023 (the “Meeting”), and in accordance with Section 11.3 of NI 51-102, continuous disclosure obli |
|
| September 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of September 2023 Commission File Number: 001-39131 LIMINAL BIOSCIENCES INC. (Translation of registrant’s name into English) 440 Armand-Frappier Boulevard, Suite 300 Laval, Québec H7V 4B4 (Address |
|
| September 12, 2023 |
EX-99.(A)(2)(VII) Exhibit (a)(2)(vii) These materials are important and require your immediate attention. If you are a shareholder of Liminal BioSciences Inc. (“Liminal BioSciences” or the “Company”) and have any questions regarding the information contained in this Supplement to the Management Information Circular dated August 16, 2023, please contact Carson Proxy Advisors, the Company’s proxy so |
|
| September 12, 2023 |
SC 13E3/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13E-3 (Amendment No. 1) RULE 13e-3 TRANSACTION STATEMENT UNDER SECTION 13(e) OF THE SECURITIES EXCHANGE ACT OF 1934 Liminal BioSciences Inc. (Name of the Issuer) Liminal BioSciences Inc. Structured Alpha LP Thomvest Asset Management Ltd. Peter J. Thomson Eugene Siklos (Name of Persons Filing Statement) Commo |
|
| September 12, 2023 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of September 2023 Commission File Number: 001-39131 LIMINAL BIOSCIENCES INC. (Translation of registrant’s name into English) 440 Armand-Frappier Boulevard, Suite 300 Laval, Québec H7V 4B4 (Add |
|
| September 12, 2023 |
EX-99.1 Exhibit 99.1 LIMINAL BIOSCIENCES FILES AMENDED SCHEDULE 13E-3 AND SUPPLEMENT TO THE MANAGEMENT INFORMATION CIRCULAR LAVAL, Quebec, Canada, and CAMBRIDGE, England – September 12, 2023 - Liminal BioSciences Inc. (NASDAQ: LMNL) (“Liminal BioSciences” or the “Company”), announced that an amendment to the previously filed Schedule 13E-3 will be filed to address comments raised by the Securities |
|
| September 12, 2023 |
September 12, 2023 VIA EMAIL AND EDGAR Securities and Exchange Commission Division of Corporation Finance Office of Mergers & Acquisitions Washington, D. |
|
| August 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of August 2023 Commission File Number: 001-39131 LIMINAL BIOSCIENCES INC. (Translation of registrant’s name into English) 440 Armand-Frappier Boulevard, Suite 300 Laval, Québec H7V 4B4 (Address of |
|
| August 17, 2023 |
8th Floor, 100 University Avenue Toronto, Ontario M5J 2Y1 www.computershare.com Exhibit 99.3 8th Floor, 100 University Avenue Toronto, Ontario M5J 2Y1 www.computershare.com 000001 Mr A Sample Designation (if any) Security Class Add1 123 Add2 Holder Account Number add3 add4 add5 C1234567890 XXX add6 Fold Form of Proxy—Special Meeting to be held on September 15, 2023 This Form of Proxy is solicited by and on behalf of management of the Company. Notes to proxy 1. Every adjournme |
|
| August 17, 2023 |
Liminal BioSciences Inc. Notice of Special Meeting of Shareholders Exhibit 99.2 Liminal BioSciences Inc. Notice of Special Meeting of Shareholders Laval, Québec, Canada, August 16, 2023. NOTICE IS HEREBY GIVEN that, pursuant to an interim order of the Ontario Superior Court of Justice (Commercial List) dated August 16, 2023 (as same may be amended, the “Interim Order”), a special meeting (the “Meeting”) of holders (the “Shareholders”) of common shares (the “Share |
|
| August 17, 2023 |
8th Floor, 100 University Avenue Toronto, Ontario M5J 2Y1 www.computershare.com EX-(A)(2)(II) Exhibit (a)(2)(ii) 8th Floor, 100 University Avenue Toronto, Ontario M5J 2Y1 www. |
|
| August 17, 2023 |
LIMINAL BIOSCIENCES INC. (the “Company”) CERTIFICATE OF OFFICER EX-99.5 Exhibit 99.5 LIMINAL BIOSCIENCES INC. (the “Company”) CERTIFICATE OF OFFICER TO: The Canadian Securities Regulatory Authorities in each of the Provinces and Territories of Canada RE: Abridgement of time pursuant to National Instrument 54-101 – Communication With Beneficial Owners of Securities of a Reporting Issuer (“NI 54-101”) DATE: August 16, 2023 The undersigned, Marie Iskra, duly appo |
|
| August 17, 2023 |
Exhibit (c)(2) PROJECT LYNX Special Committee Update June 9, 2023 Market Outreach Overview ⚫ At the Special Committee’s direction, BMO contacted selected third parties for potential interest in acquiring the Lynx business / assets ⚫ Outreach process designed to efficiently determine potential interest from qualified parties in pursuing a competing transaction ⚫ Two groups of counterparties were id |
|
| August 17, 2023 |
EXHIBIT 107 Calculation of Filing Fee Tables Schedule 13E-3 (Form Type) Liminal Biosciences Inc. |
|
| August 17, 2023 |
8th Floor, 100 University Avenue Toronto, Ontario M5J 2Y1 www.computershare.com Exhibit (a)(2)(iii) 8th Floor, 100 University Avenue Toronto, Ontario M5J 2Y1 www. |
|
| August 17, 2023 |
Exhibit 99.1 These materials are important and require your immediate attention. They require shareholders of Liminal BioSciences Inc. to make important decisions. If you are in doubt about how to make such decisions, please contact your financial, legal, tax or other professional advisors. If you are a shareholder of Liminal BioSciences Inc. and have any questions regarding the information contai |
|
| August 17, 2023 |
Exhibit (c)(3) PRELIMINARY AND CONFIDENTIAL INFORMATION – SUBJECT TO FURTHER REVIEW AND REVISION Preliminary Discussion Materials for Special Committee June 20, 2023 PRELIMINARY AND CONFIDENTIAL INFORMATION – SUBJECT TO FURTHER REVIEW AND REVISION SITUATION OVERVIEW Section 1: Situation Overview Section 1 Situation Overview Section 2 Preliminary Financial Analysis Appendix 1 PROJECT LYNX PRELIMINARY AND CONFIDENTIAL INFORMATION – SUBJECT TO FURTHER REVIEW AND REVISION SITUATION OVERVIEW Overview ⚫ On April 5, 2023, Structured Alpha LP ( SALP ) publicly released an unsolicited non-binding proposal to acquire all of the issued and outstanding common shares of Liminal BioSciences Inc. |
|
| August 17, 2023 |
SC 13E3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13E-3 RULE 13e-3 TRANSACTION STATEMENT UNDER SECTION 13(e) OF THE SECURITIES EXCHANGE ACT OF 1934 Liminal BioSciences Inc. (Name of the Issuer) Liminal BioSciences Inc. Structured Alpha LP Thomvest Asset Management Ltd. Peter J. Thomson Eugene Siklos (Name of Persons Filing Statement) Common Shares, no par val |
|
| August 17, 2023 |
Exhibit (c)(4) PRELIMINARY AND CONFIDENTIAL INFORMATION – SUBJECT TO FURTHER REVIEW AND REVISION Preliminary DCF Sensitivity June 21, 2023 PRELIMINARY AND CONFIDENTIAL INFORMATION – SUBJECT TO FURTHER REVIEW AND REVISION PRELIMINARY DCF SENSITIVITY Preliminary Discounted Cash Flow Sensitivity – GPR84 IMPLIED EQUITY VALUE PER SHARE ILLUSTRATIVE PF OWNERSHIP ON FULLY FUNDED BASIS For Informational Reference Low High (1) Reflects Illustrative Equity Financing For $677. |
|
| August 17, 2023 |
Exhibit (c)(5) Presentation to Special Committee July 11, 2023 SITUATION OVERVIEW Section 1: Situation Overview Section 1 Situation Overview Section 2 Financial Analysis Appendix 1 PROJECT LYNX SITUATION OVERVIEW Overview ⚫ Structured Alpha LP (“SALP”), an entity controlled by Thomvest Asset Management (collectively with SALP, “Thomvest”), owns 64% of the common shares of Liminal BioSciences Inc. |
|
| August 17, 2023 |
Exhibit (a)(2)(i) These materials are important and require your immediate attention. |
|
| August 17, 2023 |
LETTER OF TRANSMITTAL FOR REGISTERED HOLDERS OF COMMON SHARES LIMINAL BIOSCIENCES INC. EX-(A)(2)(IV) Exhibit (a)(2)(iv) You are strongly urged to read the accompanying Liminal BioSciences Inc. |
|
| August 17, 2023 |
LETTER OF TRANSMITTAL FOR REGISTERED HOLDERS OF COMMON SHARES LIMINAL BIOSCIENCES INC. Exhibit 99.4 You are strongly urged to read the accompanying Liminal BioSciences Inc. Management Information Circular dated August 16, 2023 before completing this Letter of Transmittal. This is not a form of proxy for the purposes of the special meeting of shareholders of Liminal Biosciences Inc. to be held on September 15, 2023. A form of proxy has been distributed by Liminal Biosciences Inc. for |
|
| August 16, 2023 |
LIMINAL BIOSCIENCES OBTAINS INTERIM ORDER FOR PROPOSED ARRANGEMENT WITH STRUCTURED ALPHA LP EXHIBIT 99.1 LIMINAL BIOSCIENCES OBTAINS INTERIM ORDER FOR PROPOSED ARRANGEMENT WITH STRUCTURED ALPHA LP LAVAL, QC and CAMBRIDGE, England, Aug. 16, 2023 /CNW/ - Liminal BioSciences Inc. (NASDAQ: LMNL) ("Liminal BioSciences" or the "Company"), announced today that the Ontario Superior Court of Justice (Commercial List) (the "Court") has issued an interim order (the "Interim Order") in connection wi |
|
| August 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of August 2023 Commission File Number: 001-39131 LIMINAL BIOSCIENCES INC. (Translation of registrant’s name into English) 440 Armand-Frappier Boulevard, Suite 300 Laval, Québec H7V 4B4 (Address of |
|
| August 8, 2023 |
FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE EXHIBIT 99.5 FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE I, Nicole Rusaw, Chief Financial Officer of Liminal BioSciences Inc., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the “interim filings”) of Liminal BioSciences Inc. (the “issuer”) for the interim period ended June 30, 2023. 2. No misrepresentations: Based on m |
|
| August 8, 2023 |
EXHIBIT 99.2 Management's discussion and analysis of Liminal BioSciences Inc. For the quarter and six months ended June 30, 2023 Management's discussion and analysis For the quarter ended June 30, 2023 This Management’s Discussion and Analysis, or MD&A, is intended to help the reader to better understand Liminal BioSciences Inc.’s ("Liminal" or "the Company") operations, financial performance and |
|
| August 8, 2023 |
FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE EXHIBIT 99.4 FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE I, Bruce Pritchard, Chief Executive Officer of Liminal BioSciences Inc., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the “interim filings”) of Liminal BioSciences Inc. (the “issuer”) for the interim period ended June 30, 2023. 2. No misrepresentations: Based o |
|
| August 8, 2023 |
Liminal BioSciences Reports Second Quarter Financial Results 2023 EXHIBIT 99.1 Liminal BioSciences Reports Second Quarter Financial Results 2023 • Provided R&D update on GPCR-targeted pipeline, including nomination of lead candidate for OXER1 antagonist program • Closed June 30, 2023 with over CAD 19 million cash on hand, expecting to provide cash runway into December 2023 • Net loss from continuing operations of CAD 9 million during the quarter ended June, 2023 |
|
| August 8, 2023 |
Equity (deficiency) attributable to owners of the parent EXHIBIT 99.3 Interim condensed consolidated financial statements of Liminal BioSciences Inc. For the quarter and six months ended June 30, 2023 LIMINAL BIOSCIENCES INC. CONSOLIDATED STATEMENTS OF FINANCIAL POSITION (In thousands of Canadian dollars) (Unaudited) June 30, December 31, 2023 2022 ASSETS Current assets Cash and cash equivalents $ 19,312 $ 37,144 Accounts receivable 788 1,177 Prepaids 1 |
|
| August 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of August 2023 Commission File Number: 001-39131 LIMINAL BIOSCIENCES INC. (Translation of registrant’s name into English) 440 Armand-Frappier Boulevard, Suite 300 Laval, Québec H7V 4B4 (Address of |
|
| August 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of August 2023 Commission File Number: 001-39131 LIMINAL BIOSCIENCES INC. (Translation of registrant’s name into English) 440 Armand-Frappier Boulevard, Suite 300 Laval, Québec H7V 4B4 (Address of |
|
| August 2, 2023 | ||
| July 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D/A (Amendment No. 3) UNDER THE SECURITIES EXCHANGE ACT OF 1934 Liminal BioSciences Inc. (Name of Issuer) Common Shares, no par value (Title of Class of Securities) 53272L202 (CUSIP Number) Eugene Siklos, President c/o Thomvest Asset Management Ltd. 65 Queen Street West, Suite 2400 Toronto, Ontario, M5H 2M8 (416) 36 |
|
| July 12, 2023 |
Exhibit 99.2 July 11, 2023 Structured Alpha LP c/o Thomvest Asset Management Ltd. 65 Queen Street West, Suite 2400 Toronto, ON Canada M5H 2M8 Dear Sirs/Madams: Re: Voting and Support Agreement I, the individual whose name is set forth on the signature page attached to this Agreement, understand that Structured Alpha LP (the “Purchaser” or “you”) and Liminal BioSciences Inc. (the “Company”) wish to |
|
| July 12, 2023 |
Exhibit 99.1 Execution Version ARRANGEMENT AGREEMENT AMONG: STRUCTURED ALPHA LP – and – LIMINAL BIOSCIENCES INC. July 11, 2023 TABLE OF CONTENTS Article 1 INTERPRETATION 1 1.1 Definitions 1 1.2 Certain Rules of Interpretation 11 1.3 Schedules 12 Article 2 THE ARRANGEMENT 13 2.1 The Arrangement 13 2.2 Court Proceedings and Materials 13 2.3 Interim Order 14 2.4 Company Circular 15 2.5 The Company Me |
|
| July 12, 2023 |
EXHIBIT 99.1 Liminal BioSciences Announces Arrangement Agreement with Structured Alpha LP Liminal BioSciences minority shareholders to receive US$8.50 in cash per share in "go private" transaction LAVAL, QC, CAMBRIDGE, England, and TORONTO, July 12, 2023 /CNW/ - Liminal BioSciences Inc. ("Liminal BioSciences" or the "Company") (NASDAQ: LMNL) and Structured Alpha LP ("SALP"), a fund managed by Thom |
|
| July 12, 2023 |
FORM 51-102F3 MATERIAL CHANGE REPORT Exhibit 99.3 FORM 51-102F3 MATERIAL CHANGE REPORT 1. Name and Address of Company Liminal BioSciences Inc. ("Liminal BioSciences" or the "Company") 440, Armand-Frappier Blvd., Suite 300 Laval, Québec H7V 4B4 2. Date of Material Change July 11, 2023 3. News Release A news release disclosing the nature and substance of the material change was disseminated by Liminal BioSciences on July 12, 2023 on ne |
|
| July 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of July 2023 Commission File Number: 001-39131 LIMINAL BIOSCIENCES INC. (Translation of registrant’s name into English) 440 Armand-Frappier Boulevard, Suite 300 Laval, Québec H7V 4B4 (Address of p |
|
| July 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of July 2023 Commission File Number: 001-39131 LIMINAL BIOSCIENCES INC. (Translation of registrant’s name into English) 440 Armand-Frappier Boulevard, Suite 300 Laval, Québec H7V 4B4 (Address of p |
|
| June 5, 2023 |
6-K 1 votingresults-june20.htm 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of June 2023 Commission File Number: 001-39131 LIMINAL BIOSCIENCES INC. (Translation of registrant’s name into English) 440 Armand-Frappier Boulevard, Suite 300 |
|
| June 5, 2023 |
Liminal BioSciences Announces Voting Results of its 2023 Annual General Meeting of Shareholders Press Release For immediate release Liminal BioSciences Announces Voting Results of its 2023 Annual General Meeting of Shareholders LAVAL, CANADA, and CAMBRIDGE, ENGLAND –June 5, 2023 – Liminal BioSciences Inc. |
|
| June 5, 2023 |
EXHIBIT 99.2 VIA SEDAR June 5, 2023 Alberta Securities Commission Autorité des marchés financiers (Québec) British Columbia Securities Commission Manitoba Securities Commission New Brunswick Securities Commission Service Newfoundland and Labrador Nova Scotia Securities Commission Ontario Securities Commission Prince Edward Island Securities Office Saskatchewan Financial Services Commission Re: Rep |
|
| June 2, 2023 |
GPCR DRUG DEVELOPMENT INVOLVING CHALLENGING, HIGH-VALUE TARGETS SEEKING GLOBAL & REGIONAL CO-DEVELOPMENT PARTNERS TO ACCELERATE THE PATH TO MARKET JUNE 2023 NASDAQ: LMNL Forward–looking information includes statements concerning, among other things: advancement of Liminal Biosciences' candidates or development programs, including the timing and outcome of the potential development of the Company's |
|
| June 2, 2023 |
Liminal BioSciences Provides R&D Update EXHIBIT 99.1 Liminal BioSciences Provides R&D Update LMNL6326 nominated as lead preclinical candidate for OXER1 antagonist development program, targeting the treatment of eosinophil-driven diseases Advancement of clinical trial application (CTA) enabling preclinical studies of LMNL6511 to support CTA filing for Phase 1 clinical trial in H2 2023 Insights gained from In Vivo preclinical studies of L |
|
| June 2, 2023 |
6-K 1 corporatepresentation-.htm 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of June 2023 Commission File Number: 001-39131 LIMINAL BIOSCIENCES INC. (Translation of registrant’s name into English) 440 Armand-Frappier Boulevard, Suite 30 |
|
| June 2, 2023 |
6-K 1 liminalbio6k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of June 2023 Commission File Number: 001-39131 LIMINAL BIOSCIENCES INC. (Translation of registrant’s name into English) 440 Armand-Frappier Boulevard, Suite 300 Lav |
|
| May 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of May 2023 Commission File Number: 001-39131 LIMINAL BIOSCIENCES INC. (Translation of registrant’s name into English) 440 Armand-Frappier Boulevard, Suite 300 Laval, Québec H7V 4B4 (Address of pr |
|
| May 9, 2023 |
Equity (deficiency) attributable to owners of the parent Exhibit 99.3 Interim condensed consolidated financial statements of Liminal BioSciences Inc. For the quarter ended March 31, 2023 LIMINAL BIOSCIENCES INC. CONSOLIDATED STATEMENTS OF FINANCIAL POSITION (In thousands of Canadian dollars) (Unaudited) March 31, December 31, 2023 2022 ASSETS Current assets Cash and cash equivalents $ 26,942 $ 37,144 Accounts receivable 1,030 1,177 Prepaids 2,255 2,997 |
|
| May 9, 2023 |
FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE EXHIBIT 99.5 FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE I, Nicole Rusaw, Chief Financial Officer of Liminal BioSciences Inc., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the “interim filings”) of Liminal BioSciences Inc. (the “issuer”) for the interim period ended March 31, 2023. 2. No misrepresentations: Based on |
|
| May 9, 2023 |
Liminal BioSciences Reports First Quarter Financial Results 2023 Exhibit 99.1 Liminal BioSciences Reports First Quarter Financial Results 2023 • GPR84 antagonist program and OXER1 antagonist program on track to meet previously stated milestones in 2023 • Closed March 31, 2023 with just over CAD26.9 million cash on hand, expecting to provide cash runway into early 2024 • Net loss from continuing operations of CAD 7.4 million during the quarter ended March 31, 20 |
|
| May 9, 2023 |
FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE EXHIBIT 99.4 FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE I, Bruce Pritchard, Chief Executive Officer of Liminal BioSciences Inc., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the “interim filings”) of Liminal BioSciences Inc. (the “issuer”) for the interim period ended March 31, 2023. 2. No misrepresentations: Based |
|
| May 9, 2023 |
Exhibit 99.2 Management's discussion and analysis of Liminal BioSciences Inc. For the quarter ended March 31, 2023 Management's discussion and analysis For the quarter ended March 31, 2023 This Management’s Discussion and Analysis, or MD&A, is intended to help the reader to better understand Liminal BioSciences Inc.’s ("Liminal" or "the Company") operations, financial performance and results of op |
|
| May 8, 2023 |
EX-99.1 2 ex991.htm PRESS RELEASE DATED MAY 8, 2023 EXHIBIT 99.1 The Special Committee of the Board of Directors of Liminal Biosciences Retains an Independent Financial Advisor in Response to Unsolicited Non-Binding Transaction Proposal LAVAL, QC and CAMBRIDGE, England, May 8, 2023 /CNW/ - Liminal BioSciences Inc. (NASDAQ: LMNL) ("Liminal BioSciences" or the "Company"), re-confirms that the board |
|
| May 8, 2023 |
6-K 1 liminalbio6k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of May 2023 Commission File Number: 001-39131 LIMINAL BIOSCIENCES INC. (Translation of registrant’s name into English) 440 Armand-Frappier Boulevard, Suite 300 Lava |
|
| May 2, 2023 | ||
| May 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of May 2023 Commission File Number: 001-39131 LIMINAL BIOSCIENCES INC. (Translation of registrant’s name into English) 440 Armand-Frappier Boulevard, Suite 300 Laval, Québec H7V 4B4 (Address of pr |
|
| May 2, 2023 | ||
| May 2, 2023 | ||
| May 2, 2023 |
Notice of Annual Meeting of Shareholders April 14, 2023 Exhibit 99.2 Notice of Annual Meeting of Shareholders April 14, 2023 NOTICE OF 2023 ANNUAL MEETING OF SHAREHOLDERS AND NOTICE OF AVAILABILITY OF MEETING MATERIALS 1 Notice of Meeting The Annual Meeting of shareholders (the "Meeting") of Liminal BioSciences Inc. (the "Company" or "Liminal BioSciences") will be conducted as a virtual only meeting via a live webcast on Monday, June 5, 2023 at 8:30 a. |
|
| May 2, 2023 |
Exhibit 99.1 Notice of Annual Meeting of Shareholders and Management Information Circular April 14, 2023 Table of Contents NOTICE OF 2023 ANNUAL MEETING OF SHAREHOLDERS AND NOTICE OF AVAILABILITY OF MEETING MATERIALS 4 1 Notice of Meeting 4 1.1 Notice-and-Access 4 1.2 How to access the Meeting Materials and the Financial Statements 5 1.3 How to request a paper copy of the Meeting Materials and of |
|
| April 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D/A (Amendment No. 2) UNDER THE SECURITIES EXCHANGE ACT OF 1934 Liminal BioSciences Inc. (Name of Issuer) Common Shares, no par value (Title of Class of Securities) 53272L202 (CUSIP Number) Eugene Siklos, President c/o Thomvest Asset Management Ltd. 65 Queen Street West, Suite 2400 Toronto, Ontario, M5H 2M8 (416) 36 |
|
| April 5, 2023 |
EX-99.7 2 tm2311769d1ex99-7.htm EXHIBIT 99.7 Exhibit 99.7 April 4, 2023 The Board of Directors Liminal Biosciences Inc. 4400, Boulevard Armand-Frappier Laval, QC H7B 4B4 Attention: Alek Krstajic, Chairman Bruce Pritchard, Chief Executive Officer Re: Transaction Proposal Dear Sirs: As you are aware, Structured Alpha LP (“SALP”) owns 1,987,622 common shares of Liminal Biosciences Inc. (“LMNL”), repr |
|
| April 5, 2023 |
THOMVEST SUBMITS PROPOSAL TO ACQUIRE LIMINAL BIOSCIENCES ON AN ALL CASH BASIS EX-99.8 3 tm2311769d1ex99-8.htm EXHIBIT 99.8 Exhibit 99.8 THOMVEST SUBMITS PROPOSAL TO ACQUIRE LIMINAL BIOSCIENCES ON AN ALL CASH BASIS Toronto, Ontario – April 5, 2023: Thomvest Asset Management Ltd. (“Thomvest”) today announced that it has made a non-binding, all cash proposal (the “Proposal”) to acquire the outstanding common shares (“Common Shares”) of Liminal BioSciences Inc. (Nasdaq: LMNL) ( |
|
| April 5, 2023 |
Liminal Biosciences Confirms Receipt of Unsolicited Non-Binding Transaction Proposal EXHIBIT 99.1 Liminal Biosciences Confirms Receipt of Unsolicited Non-Binding Transaction Proposal LAVAL, QC and CAMBRIDGE, England, April 5, 2023 /CNW/ - Liminal BioSciences Inc. (NASDAQ: LMNL) ("Liminal BioSciences" or the "Company"), confirms that following close of markets on April 4, 2023, the Board of Directors of the Company (the "Board") received a non-binding proposal from Structured Alpha |
|
| April 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of April 2023 Commission File Number: 001-39131 LIMINAL BIOSCIENCES INC. (Translation of registrant’s name into English) 440 Armand-Frappier Boulevard, Suite 300 Laval, Québec H7V 4B4 (Address of |
|
| March 31, 2023 |
Exhibit 99.1 1500 Robert-Bourassa Blvd., 7th Floor Montreal QC, H3A 3S8 www.computershare.com March 31, 2023 To: All Canadian Securities Regulatory Authorities Subject: LIMINAL BIOSCIENCES INC Dear Sir/Madam: We advise of the following with respect to the upcoming Meeting of Security Holders for the subject Issuer: Meeting Type : Annual General Meeting Record Date for Notice of Meeting : April 26, |
|
| March 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of March 2023 Commission File Number: 001-39131 LIMINAL BIOSCIENCES INC. (Translation of registrant’s name into English) 440 Armand-Frappier Boulevard, Suite 300 Laval, Québec H7V 4B4 (Address of |
|
| March 15, 2023 |
Exhibit 2.1 The following describes our issued share capital, highlights certain differences in corporate law in Canada and the United States and summarizes certain material provisions of our articles of incorporation and bylaws. Please note that this summary is not intended to be exhaustive. For further information, please refer to the full version of our articles of incorporation and by-laws, wh |
|
| March 15, 2023 |
Exhibit 13.2 Certification by the Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 In connection with the Annual Report of Liminal BioSciences Inc. (the “Company”) on Form 20-F for the fiscal year ended December 31, 2022 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Nico |
|
| March 15, 2023 |
Consent of PricewaterhouseCoopers LLP Exhibit 15.1 Consent of Independent Registered Public Accounting firm We hereby consent to the incorporation by reference into the Registration Statements on Form S-8 (No. 333-235692) and Form F-3 (Nos. 333-251055, 333-245703 and 333-251065) of Liminal BioSciences Inc. of our report dated March 14, 2023 relating to the consolidated financial statements of Liminal BioSciences Inc., which appears in |
|
| March 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of March 2023 Commission File Number: 001-39131 LIMINAL BIOSCIENCES INC. (Translation of registrant’s name into English) 440 Armand-Frappier Boulevard, Suite 300 Laval, Québec H7V 4B4 (Address of |
|
| March 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXC |
|
| March 15, 2023 |
Exhibit 13.1 Certification by the Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 In connection with the Annual Report of Liminal BioSciences Inc. (the “Company”) on Form 20-F for the fiscal year ended December 31, 2022 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Bruc |
|
| March 15, 2023 |
Liminal BioSciences Reports Fourth Quarter and Year Ended 2022 Financial Results Exhibit 99.1 Liminal BioSciences Reports Fourth Quarter and Year Ended 2022 Financial Results • CTA-enabling work on track to seek approval to commence Phase 1 clinical trial of LMNL6511 during the second half of 2023 • Addition of GPR40 agonist discovery program aiming for the development of a novel liver-safe GPR40 agonist for the treatment of type 2 diabetes • Closed December 31, 2022 with just |
|
| March 15, 2023 |
Exhibit 12.1 Certification by the Principal Executive Officer pursuant to Securities Exchange Act Rules 13a-14(a) and 15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Bruce Pritchard, certify that: 1. I have reviewed this annual report on Form 20-F of Liminal BioSciences Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material |
|
| March 15, 2023 |
Exhibit 12.2 Certification by the Principal Financial Officer pursuant to Securities Exchange Act Rules 13a-14(a) and 15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Nicole Rusaw, certify that: 1. I have reviewed this annual report on Form 20-F of Liminal BioSciences Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fa |
|
| March 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of March 2023 Commission File Number: 001-39131 LIMINAL BIOSCIENCES INC. (Translation of registrant’s name into English) 440 Armand-Frappier Boulevard, Suite 300 Laval, Québec H7V 4B4 (Address of |
|
| March 13, 2023 |
Liminal BioSciences to Report Fourth Quarter and Year Ended 2022 Financial Results on March 15, 2023 EX-99.1 2 ex991.htm PRESS RELEASE DATED MARCH 13, 2023 EXHIBIT 99.1 Liminal BioSciences to Report Fourth Quarter and Year Ended 2022 Financial Results on March 15, 2023 LAVAL, QC, and CAMBRIDGE, England, March 13, 2023 /CNW/ - Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company"), today announced that it plans to report its fourth quarter and year ended 2022 financial re |
|
| February 15, 2023 |
Liminal BioSciences Regains Compliance with NASDAQ Minimum Bid Price Requirement EXHIBIT 99.1 Liminal BioSciences Regains Compliance with NASDAQ Minimum Bid Price Requirement LAVAL, QC, Feb. 15, 2023 /CNW/ - Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company"), announced that it has received written notice from The Nasdaq Stock Market LLC ("Nasdaq") that the Company has regained compliance with Nasdaq's minimum bid price for continued listing on the |
|
| February 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of February 2023 Commission File Number: 001-39131 LIMINAL BIOSCIENCES INC. (Translation of registrant’s name into English) 440 Armand-Frappier Boulevard, Suite 300 Laval, Québec H7V 4B4 (Address |
|
| February 2, 2023 |
FORM 51–102F3 MATERIAL CHANGE REPORT Exhibit 99.2 FORM 51–102F3 MATERIAL CHANGE REPORT Item 1. Name and Address of Company Liminal BioSciences Inc. (“Liminal” or the “Company”) 440 Armand-Frappier Blvd., Suite 300 Laval, QC, H7V 4B4 Item 2. Date of Material Change February 1, 2023. Item 3. News Release A press release describing the material change referred to in this report was disseminated by Liminal on January 26, 2023 on newswire |
|
| February 2, 2023 |
Certificate of Amendment of Liminal BioSciences Inc. dated January 25, 2023 |
|
| February 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of February 2023 Commission File Number: 001-39131 LIMINAL BIOSCIENCES INC. (Translation of registrant’s name into English) 440 Armand-Frappier Boulevard, Suite 300 Laval, Québec H7V 4B4 (Address |
|
| January 26, 2023 |
Liminal BioSciences Announces Reverse Stock Split EXHIBIT 99.1 Liminal BioSciences Announces Reverse Stock Split LAVAL, QC and CAMBRIDGE, England, Jan. 26, 2023 /CNW/ - Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company"), announced that a consolidation of all of the issued and outstanding common shares of the Company ("Common Shares") on the basis of a consolidation ratio of ten (10) pre-consolidation Common Shares fo |
|
| January 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of January 2023 Commission File Number: 001-39131 LIMINAL BIOSCIENCES INC. (Translation of registrant’s name into English) 440 Armand-Frappier Boulevard, Suite 300 Laval, Québec H7V 4B4 (Address o |
|
| January 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of January 2023 Commission File Number: 001-39131 LIMINAL BIOSCIENCES INC. (Translation of registrant’s name into English) 440 Armand-Frappier Boulevard, Suite 300 Laval, Québec H7V 4B4 (Address o |
|
| January 20, 2023 |
EX-99.1 2 lmnl-ex991.htm EX-99.1 EXHIBIT 99.1 VIA SEDAR January 20, 2023 Alberta Securities Commission Autorité des marchés financiers (Québec) British Columbia Securities Commission Manitoba Securities Commission New Brunswick Securities Commission Service Newfoundland and Labrador Nova Scotia Securities Commission Ontario Securities Commission Prince Edward Island Securities Office Saskatchewan |
|
| January 19, 2023 |
Liminal BioSciences to Present at BIO CEO & Investor Conference EXHIBIT 99.1 Liminal BioSciences to Present at BIO CEO & Investor Conference LAVAL, QC and CAMBRIDGE, England, Jan. 19, 2023 /CNW/ - Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company"), announced that Bruce Pritchard, Chief Executive Officer at Liminal BioSciences is scheduled to present a company overview on Tuesday February 7, 2023 at 10:30am (ET) during the BIO CEO |
|
| January 19, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of January 2023 Commission File Number: 001-39131 LIMINAL BIOSCIENCES INC. (Translation of registrant’s name into English) 440 Armand-Frappier Boulevard, Suite 300 Laval, Québec H7V 4B4 (Address o |
|
| January 6, 2023 |
Liminal BioSciences Announces Priorities For 2023 EX-99.1 2 ex991.htm PRESS RELEASE DATED JANUARY 6, 2023 EXHIBIT 99.1 Liminal BioSciences Announces Priorities For 2023 Closed December 2022 with just over CAD 37 million cash on hand, expecting to provide a runway into early 2024. Plans to divest its remaining non-core assets, to further extend runway. Nominated LMNL6511 as its GPR84 Antagonist lead preclinical drug candidate. Selection of initial |
|
| January 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of January 2023 Commission File Number: 001-39131 LIMINAL BIOSCIENCES INC. (Translation of registrant?s name into English) 440 Armand-Frappier Boulevard, Suite 300 Laval, Qu?bec H7V 4B4 (Address o |
|
| January 6, 2023 |
Aiming to develop Best/First-In-Class Novel Small Molecule Therapeutics for Inflammatory, Metabolic and Fibrotic Diseases Corporate Presentation NASDAQ: LMNL January 2023 Exhibit 99. |
|
| January 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of January 2023 Commission File Number: 001-39131 LIMINAL BIOSCIENCES INC. (Translation of registrant?s name into English) 440 Armand-Frappier Boulevard, Suite 300 Laval, Qu?bec H7V 4B4 (Address o |
|
| December 22, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of December 2022 Commission File Number: 001-39131 LIMINAL BIOSCIENCES INC. (Translation of registrant’s name into English) 440 Armand-Frappier Boulevard, Suite 300 Laval, Québec H7V 4B4 (Address |
|
| December 15, 2022 |
Notice of Special Meeting of Shareholders Exhibit 99.2 |
|
| December 15, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of December 2022 Commission File Number: 001-39131 LIMINAL BIOSCIENCES INC. (Translation of registrant’s name into English) 440 Armand-Frappier Boulevard, Suite 300 Laval, Québec H7V 4B4 (Address |
|
| December 15, 2022 |
Exhibit 99.1 Notice of Special Meeting of Shareholders and Management Information Circular December 12, 2022 Table of Contents NOTICE OF SPECIAL MEETING OF SHAREHOLDERS 3 1 Notice of Meeting 3 1.1 Notice-and-Access 3 1.2 How to access the Meeting Materials 4 1.3 How to request a paper copy of the Meeting Materials 4 1.3.1 Before the Meeting 4 1.3.2 After the Meeting 4 1.4 Participating at the Meet |
|
| December 15, 2022 |
Exhibit 99.4 |
|
| December 15, 2022 |
Virtual Special Meeting User Guide Exhibit 99.5 |
|
| December 15, 2022 |
Exhibit 99.3 |
|
| November 25, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of November 2022 Commission File Number: 001-39131 LIMINAL BIOSCIENCES INC. (Translation of registrant?s name into English) 440 Armand-Frappier Boulevard, Suite 300 Laval, Qu?bec H7V 4B4 (Address |
|
| November 25, 2022 |
Liminal BioSciences Announces Holding of Special Meeting of Shareholders EXHIBIT 99.1 Liminal BioSciences Announces Holding of Special Meeting of Shareholders LAVAL, QC and CAMBRIDGE, England, Nov. 25, 2022 /CNW/ - Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company"), announced that it will be holding a virtual special meeting of shareholders on January 20th, 2023, to seek approval to amend the articles of the Company to effect a consolidati |
|
| November 10, 2022 |
Exhibit 99.1 1500 Robert-Bourassa Blvd., 7th Floor Montreal QC, H3A 3S8 www.computershare.com November 10, 2022 To: All Canadian Securities Regulatory Authorities Subject: LIMINAL BIOSCIENCES INC Dear Sir/Madam: We advise of the following with respect to the upcoming Meeting of Security Holders for the subject Issuer: Meeting Type : Special Meeting Record Date for Notice of Meeting : December 5, 2 |
|
| November 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of November 2022 Commission File Number: 001-39131 LIMINAL BIOSCIENCES INC. (Translation of registrant?s name into English) 440 Armand-Frappier Boulevard, Suite 300 Laval, Qu?bec H7V 4B4 (Address |
|
| November 9, 2022 |
EXHIBIT 99.2 Management's discussion and analysis of Liminal BioSciences Inc. For the quarter and nine months ended September 30, 2022 Management's discussion and analysis For the quarter ended September 30, 2022 This Management?s Discussion and Analysis, or MD&A, is intended to help the reader to better understand Liminal BioSciences Inc.?s ("Liminal" or "the Company") operations, financial perfo |
|
| November 9, 2022 |
FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE EXHIBIT 99.5 FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE I, Nicole Rusaw, Chief Financial Officer of Liminal BioSciences Inc., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the ?interim filings?) of Liminal BioSciences Inc. (the ?issuer?) for the interim period ended September 30, 2022. 2. No misrepresentations: Based |
|
| November 9, 2022 |
FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE EXHIBIT 99.4 FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE I, Bruce Pritchard, Chief Executive Officer of Liminal BioSciences Inc., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the ?interim filings?) of Liminal BioSciences Inc. (the ?issuer?) for the interim period ended September 30, 2022. 2. No misrepresentations: Ba |
|
| November 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of November 2022 Commission File Number: 001-39131 LIMINAL BIOSCIENCES INC. (Translation of registrant?s name into English) 440 Armand-Frappier Boulevard, Suite 300 Laval, Qu?bec H7V 4B4 (Address |
|
| November 9, 2022 |
Equity (deficiency) attributable to owners of the parent EXHIBIT 99.3 Interim condensed consolidated financial statements of Liminal BioSciences Inc. For the quarter and nine months ended September 30, 2022 LIMINAL BIOSCIENCES INC. CONSOLIDATED STATEMENTS OF FINANCIAL POSITION (In thousands of Canadian dollars) September 30, December 31, 2022 2021 ASSETS Current assets Cash and cash equivalents $ 40,752 $ 108,490 Accounts receivable 1,498 1,068 Prepaids |
|
| November 9, 2022 |
Liminal BioSciences Reports Third Quarter 2022 Financial Results and Business Highlights EXHIBIT 99.1 Liminal BioSciences Reports Third Quarter 2022 Financial Results and Business Highlights ? $40.8M of cash and cash equivalents at September 30, 2022 ? Discontinuation of fezagepras development ? Termination of legacy CDMO agreement for cash savings of $33.1 million ? Net loss from continuing operations of $4.5 million during the quarter ended September 30, 2022 compared to $9.7 millio |
|
| November 8, 2022 |
Liminal BioSciences to Report Third Quarter 2022 Financial Results on November 9, 2022 EXHIBIT 99.1 Liminal BioSciences to Report Third Quarter 2022 Financial Results on November 9, 2022 LAVAL, QC and CAMBRIDGE, England, Nov. 8, 2022 /CNW Telbec/ - Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company"), today announced that it plans to report its third quarter 2022 financial results after market close on November 9, 2022. Liminal will host a conference call |
|
| November 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of November 2022 Commission File Number: 001-39131 LIMINAL BIOSCIENCES INC. (Translation of registrant’s name into English) 440 Armand-Frappier Boulevard, Suite 300 Laval, Québec H7V 4B4 (Address |
|
| September 13, 2022 |
EX-99.1 2 lmnl-ex991.htm 99.1 Aiming to develop Best/First-In-Class Novel Small Molecule Therapeutics for Inflammatory, Metabolic and Fibrotic Diseases Corporate Presentation NASDAQ: LMNL September 2022 Safe Harbour This presentation contains forward-looking statements about Liminal BioSciences’ objectives, strategies and businesses that involve risks and uncertainties. Forward‐looking information |
|
| September 13, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of September 2022 Commission File Number: 001-39131 LIMINAL BIOSCIENCES INC. (Translation of registrant?s name into English) 440 Armand-Frappier Boulevard, Suite 300 Laval, Qu?bec H7V 4B4 (Address |
|
| September 1, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of September 2022 Commission File Number: 001-39131 LIMINAL BIOSCIENCES INC. (Translation of registrant?s name into English) 440 Armand-Frappier Boulevard, Suite 300 Laval, Qu?bec H7V 4B4 (Address |
|
| September 1, 2022 |
Liminal BioSciences Announces Listing Transfer to Nasdaq Capital Market EXHIBIT 99.1 Liminal BioSciences Announces Listing Transfer to Nasdaq Capital Market LAVAL, QC and CAMBRIDGE, England, Sept. 1, 2022 /CNW/ - Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company") announced today that it received confirmation from the Listing Qualifications Department of The Nasdaq Stock Market ("Nasdaq") that the Company's application to transfer its comm |
|
| August 29, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of August 2022 Commission File Number: 001-39131 LIMINAL BIOSCIENCES INC. (Translation of registrant?s name into English) 440 Armand-Frappier Boulevard, Suite 300 Laval, Qu?bec H7V 4B4 (Address of |
|
| August 29, 2022 |
Liminal Biosciences to Present at H.C. Wainwright 24th Annual Global Investment Conference EX-99.1 2 ex991.htm PRESS RELEASE DATED AUGUST 29, 2022 EXHIBIT 99.1 Liminal Biosciences to Present at H.C. Wainwright 24th Annual Global Investment Conference LAVAL, QC and CAMBRIDGE, England, Aug. 29, 2022 /CNW/ - Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company"), a development-stage biopharmaceutical company, announced that Bruce Pritchard, Chief Executive Officer |
|
| August 25, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of August 2022 Commission File Number: 001-39131 LIMINAL BIOSCIENCES INC. (Translation of registrant?s name into English) 440 Armand-Frappier Boulevard, Suite 300 Laval, Qu?bec H7V 4B4 (Address of |
|
| August 25, 2022 |
Liminal BioSciences Announces Termination of Legacy CDMO Contract EXHIBIT 99.1 Liminal BioSciences Announces Termination of Legacy CDMO Contract Termination results in anticipated cash savings of $33.1 million Removes last of legacy contracts associated with former plasma-derived therapeutics business LAVAL, QC and CAMBRIDGE, ENGLAND, Aug. 25, 2022 /CNW Telbec/ - Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company"), a development-stag |
|
| August 25, 2022 |
Form 51-102F3 Material Change Report Exhibit 99.2 Form 51-102F3 Material Change Report Item 1 Name and Address of Company Liminal BioSciences Inc. ("Liminal" or the "Company") 440 Armand-Frappier Blvd., Suite 300 Laval, QC, H7V 4B4 Item 2 Date of Material Change August 25, 2022 Item 3 News Release A news release with respect to the material change was disseminated through the facilities of a recognized newswire on August 25, 2022 and |
|
| August 10, 2022 |
FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE EXHIBIT 99.5 FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE I, Nicole Rusaw, Interim Chief Financial Officer of Liminal BioSciences Inc., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the ?interim filings?) of Liminal BioSciences Inc. (the ?issuer?) for the interim period ended June 30, 2022. 2. No misrepresentations: Ba |
|
| August 10, 2022 |
Liminal BioSciences Reports Second Quarter 2022 Financial Results and Business Highlights EXHIBIT 99.1 Liminal BioSciences Reports Second Quarter 2022 Financial Results and Business Highlights ? $55.8M of cash and cash equivalents at June 30, 2022 ? Discontinuation of fezagepras development ? Net loss from continuing operations of $6.5 million during the quarter ended June 30, 2022 compared to $12.6 million during the quarter ended June 30, 2021 LAVAL, CANADA, and CAMBRIDGE, ENGLAND ? |
|
| August 10, 2022 |
Exhibit 99.3 Interim condensed consolidated financial statements of Liminal BioSciences Inc. For the quarter and six months ended June 30, 2022 LIMINAL BIOSCIENCES INC. CONSOLIDATED STATEMENTS OF FINANCIAL POSITION (In thousands of Canadian dollars) June 30, December 31, 2022 2021 ASSETS Current assets Cash and cash equivalents $ 55,805 $ 108,490 Accounts receivable 1,480 1,068 Prepaids 2,877 5,07 |
|
| August 10, 2022 |
EXHIBIT 99.2 Management's discussion and analysis of Liminal BioSciences Inc. For the quarter and six months ended June 30, 2022 Management's discussion and analysis For the quarter ended June 30, 2022 This Management?s Discussion and Analysis, or MD&A, is intended to help the reader to better understand Liminal BioSciences Inc.?s ("Liminal" or "the Company") operations, financial performance and |
|
| August 10, 2022 |
FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE EXHIBIT 99.4 FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE I, Bruce Pritchard, Chief Executive Officer of Liminal BioSciences Inc., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the ?interim filings?) of Liminal BioSciences Inc. (the ?issuer?) for the interim period ended June 30, 2022. 2. No misrepresentations: Based o |
|
| August 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of August 2022 Commission File Number: 001-39131 LIMINAL BIOSCIENCES INC. (Translation of registrant?s name into English) 440 Armand-Frappier Boulevard, Suite 300 Laval, Qu?bec H7V 4B4 (Address of |
|
| July 22, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of July 2022 Commission File Number: 001-39131 LIMINAL BIOSCIENCES INC. (Translation of registrant?s name into English) 440 Armand-Frappier Boulevard, Suite 300 Laval, Qu?bec H7V 4B4 (Address of p |
|
| July 22, 2022 |
Liminal BioSciences Announces Discontinuation of Fezagepras Development EX-99.1 2 ex991.htm PRESS RELEASE DATED JULY 21, 2022 EXHIBIT 99.1 Liminal BioSciences Announces Discontinuation of Fezagepras Development LAVAL, QC and CAMBRIDGE, England, July 21, 2022 /CNW/ - Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company") today announced that it has discontinued development of fezagepras. The decision to discontinue the development of fezagepra |
|
| June 6, 2022 |
EXHIBIT 99.2 VIA SEDAR June 6, 2022 Alberta Securities Commission Autorit? des march?s financiers (Qu?bec) British Columbia Securities Commission Manitoba Securities Commission New Brunswick Securities Commission Service Newfoundland and Labrador Nova Scotia Securities Commission Ontario Securities Commission Prince Edward Island Securities Office Saskatchewan Financial Services Commission Re: Rep |
|
| June 6, 2022 |
Liminal BioSciences Announces Voting Results of its 2022 Annual General Meeting of Shareholders Exhibit 99.1 Press Release For immediate release Liminal BioSciences Announces Voting Results of its 2022 Annual General Meeting of Shareholders LAVAL, CANADA, and CAMBRIDGE, ENGLAND ?June 6, 2021 ? Liminal BioSciences Inc. (Nasdaq: LMNL) (?Liminal BioSciences? or the ?Company?) announced the voting results from its Annual General Meeting of Shareholders (?AGM?) held virtually on June 6, 2022. A t |
|
| June 6, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of June 2022 Commission File Number: 001-39131 LIMINAL BIOSCIENCES INC. (Translation of registrant?s name into English) 440 Armand-Frappier Boulevard, Suite 300 Laval, Qu?bec H7V 4B4 (Address of p |
|
| May 24, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of May 2022 Commission File Number: 001-39131 LIMINAL BIOSCIENCES INC. (Translation of registrant?s name into English) 440 Armand-Frappier Boulevard, Suite 300 Laval, Qu?bec H7V 4B4 (Address of pr |
|
| May 24, 2022 |
Aiming to develop Best/First-In-Class Novel Small Molecule Therapeutics for Inflammatory, Metabolic and Fibrotic Diseases Corporate Presentation NASDAQ: LMNL May 2022 Safe Harbour This presentation contains forward-looking statements about Liminal BioSciences? objectives, strategies and businesses that involve risks and uncertainties. |
|
| May 23, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of May 2022 Commission File Number: 001-39131 LIMINAL BIOSCIENCES INC. (Translation of registrant?s name into English) 440 Armand-Frappier Boulevard, Suite 300 Laval, Qu?bec H7V 4B4 (Address of pr |
|
| May 23, 2022 |
Exhibit 99.1 Liminal BioSciences Announces First Subject Dosed in Phase 1a Single Ascending Dose Clinical Trial of Fezagepras LAVAL, CANADA, and CAMBRIDGE, ENGLAND ? May 23, 2022 ? Liminal BioSciences Inc. (Nasdaq: LMNL) (?Liminal BioSciences? or the ?Company?), today announced that the first subject has been dosed in the Company?s Phase 1a single ascending dose (?SAD?) randomized, open label, cro |
|
| May 10, 2022 |
FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE EXHIBIT 99.4 FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE I, Bruce Pritchard, Chief Executive Officer of Liminal BioSciences Inc., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the ?interim filings?) of Liminal BioSciences Inc. (the ?issuer?) for the interim period ended March 31, 2022. 2. No misrepresentations: Based |
|
| May 10, 2022 |
Liminal BioSciences Reports First Quarter 2022 Financial Results and Business Highlights Exhibit 99.1 Liminal BioSciences Reports First Quarter 2022 Financial Results and Business Highlights ? Planned Phase 1a Single Ascending Dose (?SAD?) clinical trial of fezagepras expected to commence in Q2 2022 ? Completion of analysis of safety and pharmacokinetic (?PK?) data from Phase 1 Multiple Ascending Dose (?MAD?) clinical trial of fezagepras ? Repayment in full of the $39.1M secured loans |
|
| May 10, 2022 |
6-K 1 q12022-quarterlyrepo.htm 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of May 2022 Commission File Number: 001-39131 LIMINAL BIOSCIENCES INC. (Translation of registrant’s name into English) 440 Armand-Frappier Boulevard, Suite 300 L |
|
| May 10, 2022 |
Equity (deficiency) attributable to owners of the parent Exhibit 99.3 Interim condensed consolidated financial statements of Liminal BioSciences Inc. For the quarter ended March 31, 2022 LIMINAL BIOSCIENCES INC. CONSOLIDATED STATEMENTS OF FINANCIAL POSITION (In thousands of Canadian dollars) March 31 December 31 2022 2021 ASSETS Current assets Cash $ 61,166 $ 108,490 Accounts receivable 799 1,068 Prepaids 4,007 5,071 Assets held for sale (note 3) 829 ? |
|
| May 10, 2022 |
Exhibit 99.2 Management's discussion and analysis of Liminal BioSciences Inc. For the quarter ended March 31, 2022 Management's discussion and analysis For the quarter ended March 31, 2022 This Management?s Discussion and Analysis, or MD&A, is intended to help the reader to better understand Liminal BioSciences Inc.?s ("Liminal" or the "Company") operations, financial performance and results of op |
|
| May 10, 2022 |
FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE EXHIBIT 99.5 FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE I, Nicole Rusaw, Interim Chief Financial Officer of Liminal BioSciences Inc., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the ?interim filings?) of Liminal BioSciences Inc. (the ?issuer?) for the interim period ended March 31, 2022. 2. No misrepresentations: B |
|
| May 9, 2022 |
Liminal BioSciences to Report First Quarter 2022 Financial Results on May 10, 2022 EXHIBIT 99.1 Liminal BioSciences to Report First Quarter 2022 Financial Results on May 10, 2022 LAVAL, QC and CAMBRIDGE, ENGLAND, May 9, 2022 /CNW/ - Liminal BioSciences Inc. (NASDAQ: LMNL) ("Liminal BioSciences" or the "Company"), today announced that it plans to report its first quarter 2022 financial results after market close on May 10, 2021. Liminal will host a conference call and webcast to |
|
| May 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of May 2022 Commission File Number: 001-39131 LIMINAL BIOSCIENCES INC. (Translation of registrant?s name into English) 440 Armand-Frappier Boulevard, Suite 300 Laval, Qu?bec H7V 4B4 (Address of pr |
|
| May 9, 2022 |
Liminal Biosciences to Present at Upcoming Investor Conferences EXHIBIT 99.1 Liminal Biosciences to Present at Upcoming Investor Conferences LAVAL, QC, and CAMBRIDGE, England, May 9, 2022 /CNW/ - Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company"), a clinical-stage biopharmaceutical company, announced that Bruce Pritchard, Chief Executive Officer at Liminal BioSciences is scheduled to present a company overview at the following upc |
|
| May 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of May 2022 Commission File Number: 001-39131 LIMINAL BIOSCIENCES INC. (Translation of registrant?s name into English) 440 Armand-Frappier Boulevard, Suite 300 Laval, Qu?bec H7V 4B4 (Address of pr |
|
| May 3, 2022 |
Notice of Annual Meeting of Shareholders and Management Information Circular April 13, 2022 Exhibit 99.2 Notice of Annual Meeting of Shareholders and Management Information Circular April 13, 2022 NOTICE OF 2022 ANNUAL MEETING OF SHAREHOLDERS AND NOTICE OF AVAILABILITY OF MEETING MATERIALS 1 Notice of Meeting The Annual Meeting of shareholders (the "Meeting") of Liminal BioSciences Inc. (the "Company" or "Liminal BioSciences") will be conducted as a virtual only meeting via a live webcas |
|
| May 3, 2022 |
EX-99.4 5 lmnl-ex994.htm EX-99.4 Exhibit 99.4 |
|
| May 3, 2022 |
Exhibit 99.3 01TQRC 01TQRC 01TQRC Fold 01TQRC |
|
| May 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of May 2022 Commission File Number: 001-39131 LIMINAL BIOSCIENCES INC. (Translation of registrant?s name into English) 440 Armand-Frappier Boulevard, Suite 300 Laval, Qu?bec H7V 4B4 (Address of pr |
|
| May 3, 2022 |
Exhibit 99.1 Notice of Annual Meeting of Shareholders and Management Information Circular April 13, 2022 Table of Contents NOTICE OF 2022 ANNUAL MEETING OF SHAREHOLDERS AND NOTICE OF AVAILABILITY OF MEETING MATERIALS 4 1 Notice of Meeting 4 1.1 Notice-and-Access 4 1.2 How to access the Meeting Materials and the Financial Statements 5 1.3 How to request a paper copy of the Meeting Materials and of |
|
| May 3, 2022 | ||
| April 1, 2022 |
6-K 1 noticeofmeeting.htm 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of April 2022 Commission File Number: 001-39131 LIMINAL BIOSCIENCES INC. (Translation of registrant’s name into English) 440 Armand-Frappier Boulevard, Suite 300 Lava |
|
| April 1, 2022 |
Exhibit 99.1 April 1, 2022 1500 Robert-Bourassa Blvd., 7th Floor Montreal QC, H3A 3S8 www.computershare.com To: All Canadian Securities Regulatory Authorities Subject: LIMINAL BIOSCIENCES INC Dear Sir/Madam: We advise of the following with respect to the upcoming Meeting of Security Holders for the subject Issuer: Meeting Type : Annual General Meeting Record Date for Notice of Meeting : April 27, |
|
| March 18, 2022 |
Exhibit 12.2 Certification by the Principal Financial Officer pursuant to Securities Exchange Act Rules 13a-14(a) and 15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Bruce Pritchard, certify that: 1. I have reviewed this annual report on Form 20-F of Liminal BioSciences Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material |
|
| March 18, 2022 |
Exhibit 13.1 Certification by the Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 In connection with the Annual Report of Liminal BioSciences Inc. (the “Company”) on Form 20-F for the fiscal year ended December 31, 2021 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Bruc |
|
| March 18, 2022 |
Exhibit 4.20 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE LIMINAL BIOSCIENCES INC. HAS DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) IS THE TYPE THAT LIMINAL BIOSCIENCES INC. TREATS AS PRIVATE OR CONFIDENTIAL. ROYALTY STREAM AGREEMENT This Royalty Stream Agreement (the ?Agreement?) is entered into and effective as of the 26th day |
|
| March 18, 2022 |
Exhibit 12.1 Certification by the Principal Executive Officer pursuant to Securities Exchange Act Rules 13a-14(a) and 15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Bruce Pritchard, certify that: 1. I have reviewed this annual report on Form 20-F of Liminal BioSciences Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material |
|
| March 18, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F (Mark One) ? REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXC |
|
| March 18, 2022 |
Consent of PricewaterhouseCoopers LLP EX-15.1 9 lmnl-ex151.htm EX-15.1 Exhibit 15.1 Consent of Independent Registered Public Accounting Firm We hereby consent to the incorporation by reference in the Registration Statements on Form S-8 (No. 333-235692) and Form F-3 (Nos. 333-251055, 333-245703 and 333-251065) of Liminal BioSciences Inc. of our report dated March 17, 2022 relating to the consolidated financial statements of Liminal Bio |
|
| March 18, 2022 |
Exhibit 13.2 Certification by the Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 In connection with the Annual Report of Liminal BioSciences Inc. (the “Company”) on Form 20-F for the fiscal year ended December 31, 2021 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Bruc |
|
| March 18, 2022 |
Liminal BioSciences Reports Fourth Quarter and Year End 2021 Financial Results Exhibit 99.1 Liminal BioSciences Reports Fourth Quarter and Year End 2021 Financial Results ? Planned Phase 1a Single Ascending Dose (?SAD?) clinical trial, commencing in Q2 2022, to compare fezagepras with sodium phenylbutyrate as a nitrogen scavenger ? Repayment in full of the $39.1M secured loan and release of security on the Company?s assets ? Completion of the Phase 1 Multi-Ascending Dose (?M |
|
| March 18, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of March 2022 Commission File Number: 001-39131 LIMINAL BIOSCIENCES INC. (Translation of registrant?s name into English) 440 Armand-Frappier Boulevard, Suite 300 Laval, Qu?bec H7V 4B4 (Address of |
|
| March 18, 2022 |
Exhibit 2.1 The following describes our issued share capital, highlights certain differences in corporate law in Canada and the United States and summarizes certain material provisions of our articles of incorporation and bylaws. Please note that this summary is not intended to be exhaustive. For further information, please refer to the full version of our articles of incorporation and by-laws, wh |
|
| March 14, 2022 |
Liminal BioSciences Provides Update on Its Lead Drug Candidate Fezagepras EXHIBIT 99.1 Liminal BioSciences Provides Update on Its Lead Drug Candidate Fezagepras Analysis of PK data from Phase 1 Multi-Ascending Dose ("MAD") clinical trial completed Data observed shows that fezagepras has nitrogen scavenging properties Planned Phase 1a Single Ascending Dose ("SAD") trial, commencing in Q2 2022, to compare fezagepras with sodium phenylbutyrate as a nitrogen scavenger LAVAL |
|
| March 14, 2022 |
6-K 1 liminalbio6k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of March 2022 Commission File Number: 001-39131 LIMINAL BIOSCIENCES INC. (Translation of registrant’s name into English) 440 Armand-Frappier Boulevard, Suite 300 La |
|
| March 7, 2022 |
6-K 1 liminalbio6k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of March 2022 Commission File Number: 001-39131 LIMINAL BIOSCIENCES INC. (Translation of registrant’s name into English) 440 Armand-Frappier Boulevard, Suite 300 La |
|
| March 7, 2022 |
EX-99.1 2 ex991.htm PRESS RELEASE DATED MARCH 7, 2022 EXHIBIT 99.1 Liminal BioSciences Announces Receipt of NASDAQ Deficiency Notice Regarding Minimum Bid Price Requirement LAVAL, QC, and CAMBRIDGE, ENGLAND, March 7, 2022 /CNW/ - Liminal BioSciences Inc. (NASDAQ: LMNL) ("Liminal BioSciences" or the "Company"), announced today that on March 4, 2022, it received a written notice (the "Notice") from |
|
| February 16, 2022 |
6-K 1 liminalbio6k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of February 2022 Commission File Number: 001-39131 LIMINAL BIOSCIENCES INC. (Translation of registrant’s name into English) 440 Armand-Frappier Boulevard, Suite 300 |
|
| February 16, 2022 |
EX-99.1 2 ex991.htm PRESS RELEASE DATED FEBRUARY 16, 2022 EXHIBIT 99.1 Liminal BioSciences Repays its Secured Debt Ending its Creditor Relationship with Structured Alpha LP • Repayment eliminates total debt of $39.1M • Early Repayment results in: • Total interest savings of CA$9.1M • Immediate termination of Loan Agreement and release of security interests over all of its secured assets, including |
|
| January 27, 2022 |
6-K 1 lmnl-6k20220126.htm 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of January 2022 Commission File Number: 001-39131 LIMINAL BIOSCIENCES INC. (Translation of registrant’s name into English) 440 Armand-Frappier Boulevard, Suite 300 La |
|
| January 19, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of January 2022 Commission File Number: 001-39131 LIMINAL BIOSCIENCES INC. (Translation of registrant?s name into English) 440 Armand-Frappier Boulevard, Suite 300 Laval, Qu?bec H7V 4B4 (Address o |
|
| January 19, 2022 |
Liminal BioSciences Announces Strategic Priorities For 2022 EXHIBIT 99.1 Liminal BioSciences Announces Strategic Priorities For 2022 LAVAL, QC and CAMBRIDGE, England, Jan. 19, 2022 /CNW/ - Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company"), today provided an update in which it outlined key corporate and research and development priorities for 2022. "2021 was an instrumental year in simplifying our business strategy and providi |
|
| November 16, 2021 |
FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE EXHIBIT 99.5 FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE I, Bruce Pritchard, Principal Financial Officer of Liminal BioSciences Inc., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the ?interim filings?) of Liminal BioSciences Inc. (the ?issuer?) for the interim period ended September 30, 2021. 2. No misrepresentations |
|
| November 16, 2021 |
Management’s Discussion & Analysis for the quarter ended September 30, 2021 Exhibit 99.2 Management?s discussion and analysis of Liminal BioSciences Inc. For the quarter and nine months ended September 30, 2021 Management?s Discussion & Analysis for the quarter ended September 30, 2021 This Management?s Discussion and Analysis, or MD&A, is intended to help the reader to better understand the operations, financial performance and results of operations of Liminal BioScience |
|
| November 16, 2021 |
Liminal BioSciences Reports Third Quarter 2021 Financial Results EXHIBIT 99.1 Liminal BioSciences Reports Third Quarter 2021 Financial Results ? Closing of the Sale of a Rare Pediatric Disease Priority Review Voucher for gross proceeds of USD105M ? Closing of the Sale of the Remaining Plasma-Derived Therapeutics Business to Kedrion S.p.A ? Completion of the Clinical Phase of the Phase 1 Multi-Ascending Dose Clinical Trial in Fezagepras LAVAL, CANADA, and CAMBRI |
|
| November 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of November 2021 Commission File Number: 001-39131 LIMINAL BIOSCIENCES INC. (Translation of registrant?s name into English) 440 Armand-Frappier Boulevard, Suite 300 Laval, Qu?bec H7V 4B4 (Address |
|
| November 16, 2021 |
FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE EXHIBIT 99.4 FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE I, Bruce Pritchard, Chief Executive Officer of Liminal BioSciences Inc., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the ?interim filings?) of Liminal BioSciences Inc. (the ?issuer?) for the interim period ended September 30, 2021. 2. No misrepresentations: Ba |
|
| November 16, 2021 |
Exhibit 99.3 Condensed interim consolidated financial statements of Liminal BioSciences Inc. For the quarter and nine months ended September 30, 2021 LIMINAL BIOSCIENCES INC. CONSOLIDATED STATEMENTS OF FINANCIAL POSITION (In thousands of Canadian dollars) (Unaudited) September 30, December 31, 2021 2020 ASSETS Current assets Cash $ 116,696 $ 45,075 Accounts receivable and others 1,208 4,081 Invent |
|
| November 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of November 2021 Commission File Number: 001-39131 LIMINAL BIOSCIENCES INC. (Translation of registrant?s name into English) 440 Armand-Frappier Boulevard, Suite 300 Laval, Qu?bec H7V 4B4 (Address |
|
| November 10, 2021 |
EX-99.1 2 lmnl-ex9916.htm EX-99.1 EXHIBIT 99.1 FIRST AMENDING AGREEMENT First Amending Agreement (the "Amending Agreement") dated November 10, 2021 between Liminal BioSciences Inc. ("Purchaser") , Fairhaven Pharmaceuticals Inc. (the "Corporation"), The Royal Institution for the Advancement of Learning/McGill University (“McGill”), AMORCHEM, LIMITED PARTNERSHIP ("AmorChem LP"), Genesys Ventures III |
|
| October 15, 2021 |
Liminal BioSciences Announces Closing of Sale of Remaining Plasma-Derived Therapeutics Business Exhibit 99.1 Press Release For immediate release Liminal BioSciences Announces Closing of Sale of Remaining Plasma-Derived Therapeutics Business LAVAL, CANADA, and CAMBRIDGE, ENGLAND ? October 15, 2021 ? Liminal BioSciences Inc. (Nasdaq: LMNL) (?Liminal BioSciences? or the ?Company?), announced today that it has closed on the sale of the remainder of the Company?s plasma-derived therapeutics busin |
|
| October 15, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of October 2021 Commission File Number: 001-39131 LIMINAL BIOSCIENCES INC. (Translation of registrant?s name into English) 440 Armand-Frappier Boulevard, Suite 300 Laval, Qu?bec H7V 4B4 (Address o |
|
| October 13, 2021 |
Exhibit 99.1 Certificate of Amendment Certificat de modification Canada Business Corporations Act Loi canadienne sur les soci?t?s par actions Liminal BioSciences Inc. Corporate name / D?nomination sociale 307730-6 Corporation number / Num?ro de soci?t? I HEREBY CERTIFY that the articles of the above-named corporation are amended under section 178 of the Canada Business Corporations Act as set out |
|
| October 13, 2021 |
6-K 1 lmnl-6k20211013.htm 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of October 2021 Commission File Number: 001-39131 LIMINAL BIOSCIENCES INC. (Translation of registrant’s name into English) 440 Armand-Frappier Boulevard, Suite 300 La |
|
| October 4, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of October 2021 Commission File Number: 001-39131 LIMINAL BIOSCIENCES INC. (Translation of registrant?s name into English) 440 Armand-Frappier Boulevard, Suite 300 Laval, Qu?bec H7V 4B4 (Address o |
|
| October 4, 2021 |
EX-99.1 2 lmnl-ex9916.htm EX-99.1 Exhibit 99.1 FIRST AMENDING AGREEMENT First Amending Agreement (the "Amending Agreement") dated September 29, 2021 between Kedrion S.p.A ("Purchaser") and Liminal BioSciences Inc. ("Seller"). RECITALS: (a) Purchaser and Seller have entered into a share purchase agreement dated June 22, 2021 (the "Share Purchase Agreement"); and (b) Purchaser and Seller now wish to |
|
| September 28, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of September 2021 Commission File Number: 001-39131 LIMINAL BIOSCIENCES INC. (Translation of registrant?s name into English) 440 Armand-Frappier Boulevard, Suite 300 Laval, Qu?bec H7V 4B4 (Address |
|
| September 28, 2021 |
Liminal BioSciences Announces Closing of Sale of Priority Review Voucher Liminal BioSciences Announces Closing of Sale of Priority Review Voucher LAVAL, CANADA, and CAMBRIDGE, ENGLAND ? September 28, 2021 ? Liminal BioSciences Inc. |
|
| September 7, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of September 2021 Commission File Number: 001-39131 LIMINAL BIOSCIENCES INC. (Translation of registrant’s name into English) 440 Armand-Frappier Boulevard, Suite 300 Laval, Québec H7V 4B4 (Address |
|
| August 16, 2021 |
FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE EX-99.5 6 lmnl-ex9956.htm EX-99.5 EXHIBIT 99.5 FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE I, Murielle Lortie, Chief Financial Officer of Liminal BioSciences Inc., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the “interim filings”) of Liminal BioSciences Inc. (the “issuer”) for the interim period ended June 30, 2021. |
|
| August 16, 2021 |
FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE EX-99.4 5 lmnl-ex9947.htm EX-99.4 EXHIBIT 99.4 FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE I, Bruce Pritchard, Chief Executive Officer of Liminal BioSciences Inc., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the “interim filings”) of Liminal BioSciences Inc. (the “issuer”) for the interim period ended June 30, 2021. |
|
| August 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of August 2021 Commission File Number: 001-39131 LIMINAL BIOSCIENCES INC. (Translation of registrant?s name into English) 440 Armand-Frappier Boulevard, Suite 300 Laval, Qu?bec H7V 4B4 (Address of |
|
| August 16, 2021 |
Management’s Discussion & Analysis for the quarter ended June 30, 2021 Exhibit 99.2 Management?s discussion and analysis of Liminal BioSciences Inc. For the quarter and six months ended June 30, 2021 Management?s Discussion & Analysis for the quarter ended June 30, 2021 This Management?s Discussion and Analysis, or MD&A, is intended to help the reader to better understand the operations, financial performance and results of operations of Liminal BioSciences Inc. (or |
|
| August 16, 2021 |
Liminal BioSciences Reports Second Quarter 2021 Financial Results EXHIBIT 99.1 Liminal BioSciences Reports Second Quarter 2021 Financial Results ? Receipt of FDA Approval for Ryplazim? (plasminogen, human-tvmh) ? Receipt of a Rare Pediatric Disease Priority Review Voucher ? Signature of Agreement to Divest Plasma-Derived Therapeutics Business to Kedrion ? Closing of the Sale of Plasma Collection Centers to Kedrion ? Closing of the Sale of Plasma-Derived Therapeu |
|
| August 16, 2021 |
Exhibit 99.3 Condensed interim consolidated financial statements of Liminal BioSciences Inc. For the quarter and six months ended June 30, 2021 LIMINAL BIOSCIENCES INC. CONSOLIDATED STATEMENTS OF FINANCIAL POSITION (In thousands of Canadian dollars, except per share amounts) (Unaudited) June 30, December 31, 2021 2020 ASSETS Current assets Cash $ 29,648 $ 45,075 Accounts receivable and others 1,65 |
|
| August 13, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of August 2021 Commission File Number: 001-39131 LIMINAL BIOSCIENCES INC. (Translation of registrant’s name into English) 440 Armand-Frappier Boulevard, Suite 300 Laval, Québec H7V 4B4 (Address of |
|
| August 13, 2021 |
FORM 51 102F3 MATERIAL CHANGE REPORT EX-99.1 2 lmnl-ex9917.htm EX-99.1 EXHIBIT 99.1 FORM 51 102F3 MATERIAL CHANGE REPORT Item 1 Name and Address of Company Liminal BioSciences Inc. (the “Company” or “Liminal”) 440 Armand-Frappier Blvd., Suite 300 Laval, Québec, H7V 4B4 Item 2 Date of Material Change August 6, 2021 Item 3 News Release A news release with respect to the material change was disseminated through the facilities of a recog |
|
| August 9, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of August 2021 Commission File Number: 001-39131 LIMINAL BIOSCIENCES INC. (Translation of registrant?s name into English) 440 Armand-Frappier Boulevard, Suite 300 Laval, Qu?bec H7V 4B4 (Address of |
|
| August 9, 2021 |
Liminal BioSciences Announces Sale of Priority Review Voucher for USD105M EXHIBIT 99.1 Press Release For immediate release Liminal BioSciences Announces Sale of Priority Review Voucher for USD105M LAVAL, CANADA, and CAMBRIDGE, ENGLAND ? August 9, 2021 ? Liminal BioSciences Inc. (Nasdaq: LMNL) (?Liminal BioSciences? or the ?Company?), announced today that, its subsidiary Prometic Biotherapeutics Inc. (?PBT?) has entered into a definitive agreement to sell its Rare Pediat |
|
| July 26, 2021 |
6-K/A 1 lmnl-6ka20201230.htm 6-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K/A REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of July 2021 Commission File Number: 001-39131 LIMINAL BIOSCIENCES INC. (Translation of registrant’s name into English) 440 Armand-Frappier Boulevard, Suite 30 |
|
| July 26, 2021 |
PricewaterhouseCoopers LLP – Report of independent registered public accounting firm (Amended) EXIHIBIT 99.1 Report of Independent Registered Public Accounting Firm To the Board of Directors and the Shareholders of Liminal BioSciences Inc. Opinion on the Financial Statements We have audited the accompanying consolidated statements of financial position of Liminal BioSciences Inc. and its subsidiaries (together, the Company) as of December 31, 2020 and 2019, and the related consolidated stat |
|
| July 9, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of July 2021 Commission File Number: 001-39131 LIMINAL BIOSCIENCES INC. (Translation of registrant?s name into English) 440 Armand-Frappier Boulevard, Suite 300 Laval, Qu?bec H7V 4B4 (Address of p |
|
| July 9, 2021 |
Liminal BioSciences Announces Closing of Sale of Plasma-Derived Therapeutics Manufacturing Facility EXHIBIT 99.1 Press Release For immediate release Liminal BioSciences Announces Closing of Sale of Plasma-Derived Therapeutics Manufacturing Facility LAVAL, CANADA, and CAMBRIDGE, ENGLAND ?July 9, 2021 ? Liminal BioSciences Inc. (Nasdaq: LMNL) (?Liminal BioSciences? or the ?Company?), a clinical-stage biopharmaceutical company, announced today that it has closed on the previously announced divestme |
|
| June 25, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of June 2021 Commission File Number: 001-39131 LIMINAL BIOSCIENCES INC. (Translation of registrant?s name into English) 440 Armand-Frappier Boulevard, Suite 300 Laval, Qu?bec H7V 4B4 (Address of p |
|
| June 25, 2021 |
FORM 51 102F3 MATERIAL CHANGE REPORT EXHIBIT 99.1 FORM 51 102F3 MATERIAL CHANGE REPORT Item 1 Name and Address of Company Liminal BioSciences Inc. (the ?Company? or ?Liminal?) 440 Armand-Frappier Blvd., Suite 300 Laval, Qu?bec, H7V 4B4 Item 2Date of Material Change June 22, 2021. Item 3News Release The press release attached as Schedule ?A? was disseminated through Cision Canada on June 23, 2021 with respect to the material change an |
|
| June 25, 2021 |
EX-99.2 3 lmnl-ex9928.htm EX-99.2 Exhibit 99.2 CERTAIN IDENTIFIED INFORMATION MARKED WITH [***] HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. SHARE PURCHASE AGREEMENT among Kedrion S.p.A. as Purchaser -and- Liminal BioSciences Inc. as Seller dated June 22, 2021 113049053 TABLE OF CONTENTS Article 1 INTERPRE |
|
| June 23, 2021 |
EX-99.1 2 lmnl-ex9916.htm EX-99.1 EXHIBIT 99.1 Liminal Biosciences Announces Signature of a Share Purchase Agreement for sale of Remaining Plasma-derived Business with Kedrion LAVAL, CANADA, and CAMBRIDGE, ENGLAND –June 23, 2021 – Liminal BioSciences Inc. (Nasdaq: LMNL) (“Liminal BioSciences” or the “Company”), announced today that, Kedrion S.p.A (“Kedrion”) has exercised its option to acquire the |
|
| June 23, 2021 |
6-K 1 lmnl-6k20210622.htm 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of June 2021 Commission File Number: 001-39131 LIMINAL BIOSCIENCES INC. (Translation of registrant’s name into English) 440 Armand-Frappier Boulevard, Suite 300 Laval |
|
| June 17, 2021 |
6-K 1 lmnl-6k20210617.htm 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of June 2021 Commission File Number: 001-39131 LIMINAL BIOSCIENCES INC. (Translation of registrant’s name into English) 440 Armand-Frappier Boulevard, Suite 300 Laval |
|
| June 15, 2021 |
6-K 1 lmnl-6k20210615.htm 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of June 2021 Commission File Number: 001-39131 LIMINAL BIOSCIENCES INC. (Translation of registrant’s name into English) 440 Armand-Frappier Boulevard, Suite 300 Laval |
|
| June 4, 2021 |
EXHIBIT 99.3 VIA SEDAR June 4, 2021 Alberta Securities Commission Autorit? des march?s financiers (Qu?bec) British Columbia Securities Commission Manitoba Securities Commission New Brunswick Securities Commission Service Newfoundland and Labrador Nova Scotia Securities Commission Ontario Securities Commission Prince Edward Island Securities Office Saskatchewan Financial Services Commission Re: Rep |
|
| June 4, 2021 |
EXHIBIT 99.1 Press Release For immediate release Liminal BioSciences Announces FDA Approval for its Biologics License Application for Ryplazim? (plasminogen, human-tvmh) LAVAL, CANADA, and CAMBRIDGE, ENGLAND ?June 4, 2021 ? Liminal BioSciences Inc. (Nasdaq: LMNL) (?Liminal BioSciences? or the ?Company?) announced today that the U.S. Food & Drug Administration (FDA) has approved Ryplazim? (plasmino |
|
| June 4, 2021 |
FORM 51 102F3 MATERIAL CHANGE REPORT EXHIBIT 99.2 FORM 51 102F3 MATERIAL CHANGE REPORT 1. Name and Address of Reporting Issuer: Liminal BioSciences Inc. (the ?Company? or ?Liminal?) 440 Armand-Frappier Blvd., Suite 300 Laval, Qu?bec, H7V 4B4 2. Dates of Material Change: June 4, 2021. 3. News Release: The Company issued a press release (the ?Press Release?) today announcing the material change, which was disseminated through the facil |
|
| June 4, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of June 2021 Commission File Number: 001-39131 LIMINAL BIOSCIENCES INC. (Translation of registrant?s name into English) 440 Armand-Frappier Boulevard, Suite 300 Laval, Qu?bec H7V 4B4 (Address of p |
|
| May 28, 2021 |
FORM 51 102F3 MATERIAL CHANGE REPORT EXHIBIT 99.2 FORM 51 102F3 MATERIAL CHANGE REPORT 1. Name and Address of Reporting Issuer: Liminal BioSciences Inc. (the ?Company? or ?Liminal?) 440 Armand-Frappier Blvd., Suite 300 Laval, Qu?bec, H7V 4B4 2. Dates of Material Change: May 28, 2021. 3. News Release: The Company issued a press release (the ?Press Release?) today announcing the material change, which was disseminated through the facil |
|
| May 28, 2021 |
6-K 1 lmnl-6k20210528.htm 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of May 2021 Commission File Number: 001-39131 LIMINAL BIOSCIENCES INC. (Translation of registrant’s name into English) 440 Armand-Frappier Boulevard, Suite 300 Laval, |
|
| May 28, 2021 |
Liminal BioSciences Provides an Update on Currently Planned Clinical Activities for Fezagepras EXHIBIT 99.1 Press Release For immediate release Liminal BioSciences Provides an Update on Currently Planned Clinical Activities for Fezagepras LAVAL, CANADA, and CAMBRIDGE, ENGLAND ?May 28, 2021 ? Liminal BioSciences Inc. (Nasdaq: LMNL) (?Liminal BioSciences? or the ?Company?), a clinical-stage biopharmaceutical company, announced today that based on interim pharmacokinetic (?PK?) results from th |
|
| May 21, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of May 2021 Commission File Number: 001-39131 LIMINAL BIOSCIENCES INC. (Translation of registrant?s name into English) 440 Armand-Frappier Boulevard, Suite 300 Laval, Qu?bec H7V 4B4 (Address of pr |
|
| May 21, 2021 |
EXHIBIT 99.2 CERTAIN IDENTIFIED INFORMATION MARKED WITH [***] HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. SHARE PURCHASE AGREEMENT among Kedrion S.p.A. as Purchaser -and- Liminal BioSciences Inc. as Seller dated May 14, 2021 TABLE OF CONTENTS ARTICLE 1 INTERPRETATION 1.1 Definitions 1 1.2 Other Defined Te |
|
| May 21, 2021 |
EXHIBIT 99.3 Press Release For immediate release Liminal BioSciences Announces Closing of Divestiture of Plasma Collection Centers and Enters into Option Agreement with Kedrion LAVAL, CANADA, and CAMBRIDGE, ENGLAND ?May 21, 2021 ? Liminal BioSciences Inc. (Nasdaq: LMNL) (?Liminal BioSciences? or the ?Company?), a clinical-stage biopharmaceutical company, announced today that it has closed on the p |
|
| May 21, 2021 |
Form 51-102F3 Material Change Report EX-99.1 2 d185923dex991.htm EX-99.1 EXHIBIT 99.1 Form 51-102F3 Material Change Report Item 1 Name and Address of Company Liminal BioSciences Inc. (“Liminal” or the “Company”) 440 Armand-Frappier Blvd., Suite 300 Laval, QC, H7V 4B4 Item 2 Date of Material Change May 14, 2021 Item 3 News Release The press release attached as Schedule “A” was disseminated through Cision Canada on May 17, 2021 with re |
|
| May 17, 2021 |
EXHIBIT 99.1 Press Release For immediate release Liminal BioSciences Enters into Agreement with Kedrion to Divest Its Plasma Collection and Plasma-Derived Therapeutics Business ? Kedrion to acquire, for a total of USD 17M, 2 plasma collection centers and an option to acquire the remaining plasma-derived therapeutic business for USD 5M ? Liminal to receive up to 70% of net proceeds from sale of Pri |
|
| May 17, 2021 |
Liminal BioSciences Reports First Quarter 2021 Financial Results EXHIBIT 99.1 Press Release For immediate release Liminal BioSciences Reports First Quarter 2021 Financial Results ? Updated Business Strategy Focused on Small Molecule Therapeutics ? Kedrion to acquire, for a total of USD 17M, 2 plasma collection centers and an option to acquire the remaining plasma-derived therapeutic business for USD 5M ? Subject to Kedrion exercising said option, Liminal could |
|
| May 17, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of May 2021 Commission File Number: 001-39131 LIMINAL BIOSCIENCES INC. (Translation of registrant?s name into English) 440 Armand-Frappier Boulevard, Suite 300 Laval, Qu?bec H7V 4B4 (Address of pr |
|
| May 17, 2021 |
Management Discussion & Analysis for the quarter ended March 31, 2021 Exhibit 99.2 Management discussion and analysis of Liminal BioSciences Inc. For the quarter ended March 31, 2021 Management Discussion & Analysis for the quarter ended March 31, 2021 This Management?s Discussion and Analysis, or MD&A, is intended to help the reader to better understand Liminal BioSciences Inc.?s or Liminal or the Company operations, financial performance and results of operations, |
|
| May 17, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of May 2021 Commission File Number: 001-39131 LIMINAL BIOSCIENCES INC. (Translation of registrant’s name into English) 440 Armand-Frappier Boulevard, Suite 300 Laval, Québec H7V 4B4 (Address of pr |
|
| May 17, 2021 |
Equity (deficiency) attributable to owners of the parent Exhibit 99.3 Condensed interim consolidated financial statements of Liminal BioSciences Inc. For the quarter ended March 31, 2021 LIMINAL BIOSCIENCES INC. CONSOLIDATED STATEMENTS OF FINANCIAL POSITION (In thousands of Canadian dollars, except per share amounts) (Unaudited) March 31, December 31, 2021 2020 ASSETS Current assets Cash $ 21,564 $ 45,075 Accounts receivable and others 5,541 4,081 Inven |
|
| May 17, 2021 |
FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE EXHIBIT 99.4 FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE I, Bruce Pritchard, Chief Executive Officer of Liminal BioSciences Inc., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the ?interim filings?) of Liminal BioSciences Inc. (the ?issuer?) for the interim period ended March 31, 2021. 2. No misrepresentations: Based |
|
| May 17, 2021 |
FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE EXHIBIT 99.5 FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE I, Murielle Lortie, Chief Financial Officer of Liminal BioSciences Inc., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the ?interim filings?) of Liminal BioSciences Inc. (the ?issuer?) for the interim period ended March 31, 2021. 2. No misrepresentations: Based |
|
| May 4, 2021 |
EX-99.4 5 lmnl-ex99412.htm EX-99.4 Exhibit 99.4 8th Floor, 100 University Avenue Toronto, Ontario M5J 2Y1 www.computershare.com Security Class Holder Account Number Fold From of Proxy - Annual and Special Meeting to be held on June 4, 2021 This Form of Proxy is solicited by and on behalf of Management. Notes to proxy 1. Every holder has the right to appoint some other person or company of their ch |
|
| May 4, 2021 |
Notice of Annual and Special Meeting of Shareholders and Management Information Circular April 19, 2021 Exhibit 99. |
|
| May 4, 2021 |
Current Report of Foreign Issuer - 6-K - PROXY CIRCULAR UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of May 2021 Commission File Number: 001-39131 LIMINAL BIOSCIENCES INC. (Translation of registrant?s name into English) 440 Armand-Frappier Boulevard, Suite 300 Laval, Qu?bec H7V 4B4 (Address of pr |
|
| May 4, 2021 |
Our Website under "Investors & Media"/ "Investor Briefcase" NOTICE OF 2021 ANNUAL AND SPECIAL MEETING OF SHAREHOLDERS AND NOTICE OF AVAILABILITY OF MEETING MATERIALS 1 Notice of Meeting NOTICE IS HEREBY GIVEN THAT the Annual and Special Meeting of shareholders (the "Meeting") of Liminal BioSciences Inc. |
